TomoTherapy and Integra Radionics Partner to Develop a Suite of Stereotactic Fixation Products for the Hi-Art(R) Treatment System.MADISON, Wis. -- TomoTherapy Incorporated (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : TTPY) announced today that it has partnered with Integra Radionics radionics (rā·dē· , Inc., a subsidiary of Integra LifeSciences Holdings Corporation (NASDAQ: IART IART Impact Area Review Team IART Intraatrial Reentrant Tachycardia IART Initial Access Response Time (IBM) IART Image-Guided Adaptive Radiation Therapy ), to develop and distribute the InterFix[TM] radiosurgery radiosurgery /ra·dio·sur·gery/ (-ser´jer-e) surgery in which tissue destruction is performed by means of ionizing radiation rather than by surgical incision. kit. The kit includes a suite of fixation products that have been adapted for use in stereotactic stereotactic /ster·eo·tac·tic/ (-tak´tik) 1. characterized by precise positioning in space; said especially of discrete areas of the brain that control specific functions. 2. pertaining to stereotactic surgery. procedures using the TomoTherapy([R]) Hi*Art([R])treatment system. According to Del Coufal, vice president of marketing for TomoTherapy, the InterFix kit complements the Hi*Art treatment system well: "Radionics products are used in cancer centers around the world. With the InterFix kit, their head rings and fixation tools will work seamlessly with our system, adding to the clinical confidence our integrated CT guidance and helical delivery already make possible." Introduced in 2003, the TomoTherapy Hi*Art treatment system has been accepted for its image-guided, intensity-modulated radiation therapy intensity-modulated radiation therapy See IMRT. (IG/IMRT) capabilities. More than 100 cancer centers in 16 countries use the system to treat a range of cancers that were once treated with conventional linear accelerators. Increasingly, clinicians have also used the Hi*Art system for stereotactic radiosurgery (SRS SRS, SRS-A see slow-reacting substance. ) and stereotactic radiation therapy (SRT (1) (Source Routing Transparent) An IEEE-standard that provides bridging between Ethernet and Token Ring networks. Ethernet LANs use transparent bridging, and Token Ring LANs use source route bridging (SRB). ), where high doses of precisely targeted radiation are delivered in a single or a few treatment fractions. "More and more cancer centers around the world are adopting TomoTherapy's technology," said Christopher von Jako, general manager of Integra Radionics. "As innovators in the field of radiosurgery, it is important for us develop tools for this platform. We're excited about this opportunity." About TomoTherapy Incorporated TomoTherapy Incorporated has developed, manufactures and sells the TomoTherapy([R]) Hi*Art([R]) treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The Hi*Art treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The company completed its initial public offering in May 2007 and its stock is traded on the NASDAQ Global Market under the symbol TTPY. To learn more about TomoTherapy, please visit our Web site at www.TomoTherapy.com (c)2007 TomoTherapy Incorporated. All rights reserved. TomoTherapy, the TomoTherapy logo and Hi*Art and CTrue are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated. InterFix is a trademark of Integra LifeSciences. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion